+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 161 Pages
  • August 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5654088
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Histone Deacetylase 1 - Drugs In Development, 2022'; Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 38 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

The report 'Histone Deacetylase 1 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 7, 1, 1, 15 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Diffuse Large B-Cell Lymphoma, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Mycosis Fungoides, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Liver Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Unspecified B-Cell Lymphomas, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anal Cancer, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Gallbladder Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Introduction
  • Report Coverage
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
  • 4D Pharma Plc
  • 4SC AG
  • BioMarin Pharmaceutical Inc
  • Bristol-Myers Squibb Co
  • Curis Inc
  • GNT Biotech and Medicals Corp
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc
  • Medibiofarma SL
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • Neuroene Therapeutics LLC
  • Oceanyx Pharmaceuticals Inc
  • OnKure Inc
  • Regenacy Pharmaceuticals LLC
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Shuttle Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
  • ACY-1035 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ACY-1071 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ACY-738 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ACY-957 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • crocetin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • entinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • fimepinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • givinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • GNTbm-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • GNTbm-38 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • JBI-128 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • largazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • MBF-015 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • MitoDak - Drug Profile
  • Product Description
  • Mechanism Of Action
  • mocetinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • MRx-0029 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • MRX-1299 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • OKI-179 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • pracinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • purinostat mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RCY-1305 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RCY-1410 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • remetinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • resminostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RG-2833 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit HDAC1 and HDAC6 for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit HDAC1, HDAC2 and HDAC3 for Burkitt Lymphoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit HDAC1 and 2 for Cognitive Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit HDAC1 and HDAC2 for Hemoglobinopathies - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SP-1161 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SP-1303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • tucidinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • vorinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products
  • Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 25, 2022: Italfarmaco Group announces positive topline data from phase 3 trial showing beneficial effect of givinostat in patients with Duchenne Muscular Dystrophy
  • Jun 02, 2022: OnKure Therapeutics announces first patient dosed in the phase 1b/2 Nautilus trial of OKI-179 in combination with binimetinib in patients with advanced NRAS-mutated melanoma
  • May 05, 2022: 4SC - Resminostat and RESMAIN study update
  • Apr 08, 2022: OnKure Therapeutics announces promising preclinical data on OKI-179 in RAS-mutated tumor models presented in a late-breaking session at AACR
  • Mar 08, 2022: OnKure Therapeutics to present late-breaking preclinical data on OKI-179 at the AACR Annual Meeting 2022
  • Feb 22, 2022: 4D pharma announces FDA clearance of IND application for Live Biotherapeutic MRx0029 for the treatment of Parkinson’s disease
  • Dec 14, 2021: OnKure Therapeutics announces positive topline first-in-human phase 1 results for OKI-179
  • Dec 01, 2021: Licensing partner of Shenzhen Chipscreen Biosciences - HUYABIO International, receives regulatory approval for Chidamide monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
  • Nov 30, 2021: HUYABIO International receives regulatory approval for Hiyasta monotherapy of peripheral t-cell lymphoma In Japan
  • Nov 25, 2021: Approval for additional indication of Hiyasta tablets for relapsed or refractory PTCL treatment in Japan
  • Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
  • Oct 19, 2021: HUYABIO International launches Hiyasta as monotherapy for adult T-cell leukemia/lymphoma in Japan
  • Oct 07, 2021: Kyowa Kirin announces discontinuation for developing KHK237 (Entinostat)
  • Sep 21, 2021: HUYABIO announces first patient treated in a pivotal study of HBI-8000 combined with Opdivo (nivolumab) in patients with advanced melanoma
  • Aug 16, 2021: University of North Carolina Lineberger Comprehensive Cancer Center: Experimental drug that boosts immunotherapy shows promise in bladder cancer study
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indications, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products under Investigation by Universities/Institutes, 2022
  • Products under Investigation by Universities/Institutes, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by 4D Pharma Plc, 2022
  • Pipeline by 4SC AG, 2022
  • Pipeline by BioMarin Pharmaceutical Inc, 2022
  • Pipeline by Bristol-Myers Squibb Co, 2022
  • Pipeline by Curis Inc, 2022
  • Pipeline by GNT Biotech and Medicals Corp, 2022
  • Pipeline by Italfarmaco SpA, 2022
  • Pipeline by Jubilant Therapeutics Inc, 2022
  • Pipeline by Medibiofarma SL, 2022
  • Pipeline by Medivir AB, 2022
  • Pipeline by MEI Pharma Inc, 2022
  • Pipeline by Merck & Co Inc, 2022
  • Pipeline by Mirati Therapeutics Inc, 2022
  • Pipeline by Neuroene Therapeutics LLC, 2022
  • Pipeline by Oceanyx Pharmaceuticals Inc, 2022
  • Pipeline by OnKure Inc, 2022
  • Pipeline by Regenacy Pharmaceuticals LLC, 2022
  • Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
  • Pipeline by Shuttle Pharmaceuticals Inc, 2022
  • Pipeline by Syndax Pharmaceuticals Inc, 2022
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
  • Dormant Products, 2022
  • Discontinued Products, 2022
List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Top 10 Indications, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4D Pharma Plc
  • 4SC AG
  • BioMarin Pharmaceutical Inc
  • Bristol-Myers Squibb Co
  • Curis Inc
  • GNT Biotech and Medicals Corp
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc
  • Medibiofarma SL
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • Neuroene Therapeutics LLC
  • Oceanyx Pharmaceuticals Inc
  • OnKure Inc
  • Regenacy Pharmaceuticals LLC
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Shuttle Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd